Receptor BioLogix closes $33.6mm Series A round
Receptor BioLogix (protein therapeutics for cancer and autoimmune and metabolic disorders) brought in $33.6mm with its Series A financing round led by Skyline Ventures. Other participants were Domain Associates, Essex Woodlands Health Ventures, MedImmune Ventures, Takeda Research Investment, and Northwest Technology Ventures.
- Large Molecule
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.